38 Recruiting Studies Using Darolutamide
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Darolutamide
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described
📍 Urology Centers of Alabama — Homewood, Alabama
Prostate Cancer
View Study & Checklist ➔Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors
📍 Cedars-Sinai Medical Center — Los Angeles, California
Adult Ovarian Granulosa Cell Tumor
View Study & Checklist ➔Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
📍 Research Site — Detroit, Michigan
Metastatic Prostate Cancer
View Study & Checklist ➔Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers
📍 UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
Locally Advanced Salivary Gland Carcinoma
View Study & Checklist ➔Prostate Cancer Biomarker Enrichment and Treatment Selection
📍 Cross Cancer Institute — Edmonton, Alberta
Prostate Cancer
View Study & Checklist ➔Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
📍 Research Site — Chandler, Arizona
Metastatic Castration-Sensitive Prostate Cancer
View Study & Checklist ➔Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
📍 Prostate Cancer Centre — Calgary, Alberta
Metastatic Prostate Cancer
View Study & Checklist ➔Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Prostate Cancer
View Study & Checklist ➔INTREPId (INTermediate Risk Erection PreservatIon Trial)
📍 Stamford Hospital — Stamford, Connecticut
Prostate Cancer
View Study & Checklist ➔Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
📍 Urology Centers of Alabama, PC - Homewood — Homewood, Alabama
Cancer
View Study & Checklist ➔A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
📍 Mayo Clinic Hospital - Phoenix - Cardiology — Phoenix, Arizona
Biochemically Recurrent Prostate Cancer
View Study & Checklist ➔A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.
📍 Urology Centers of Alabama, PC - Homewood — Homewood, Alabama
Metastatic Hormone-sensitive Prostate Cancer
View Study & Checklist ➔Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Prostate Adenocarcinoma
View Study & Checklist ➔Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
Prostate Cancer
View Study & Checklist ➔Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Prostate Carcinoma
View Study & Checklist ➔Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
📍 o University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
Prostate Cancer
View Study & Checklist ➔Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer
📍 UHN Princess Margaret Hospital — Toronto, Ontario
Prostate Cancer
View Study & Checklist ➔Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
📍 Research Site — Ottawa, Ontario
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
View Study & Checklist ➔ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
📍 Grand Hopital de Charleroi - site Notre Dame — Charleroi,
Prostate Cancer Metastatic
View Study & Checklist ➔Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
📍 University of Alabama at Birmingham Hospital — Birmingham, Alabama
Prostate Cancer
View Study & Checklist ➔Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
📍 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
Metastatic Castration-resistant Prostate Cancer
View Study & Checklist ➔Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
📍 Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
mCRPC (Metastatic Castration-resistant Prostate Cancer)
View Study & Checklist ➔A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
📍 Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company — Cleveland, Ohio
Prostatic Neoplasms
View Study & Checklist ➔Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
📍 Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Anatomic Stage II Breast Cancer AJCC v8
View Study & Checklist ➔A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
📍 Florida Cancer Specialists — Sarasota, Florida
Metastatic Castration-resistant Prostate Neoplasms
View Study & Checklist ➔A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
📍 University of California San Diego Moores Cancer Center — La Jolla, California
Metastatic Castration-resistant Prostate Cancer
View Study & Checklist ➔Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
Advanced Prostate Adenocarcinoma
View Study & Checklist ➔Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
📍 Clinique Pasteur Lanroze - Brest — Brest,
High Risk Prostate Carcinoma
View Study & Checklist ➔SNV1521 in Participants With Advanced Solid Tumors
📍 Smilow Cancer Hospital at Yale New Haven — New Haven, Connecticut
Advanced Solid Tumor
View Study & Checklist ➔AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
📍 Research Site — Dothan, Alabama
Metastatic Castration-resistant Prostate Cancer
View Study & Checklist ➔TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
📍 Univ of Alabama at Birmingham — Birmingham, Alabama
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
View Study & Checklist ➔Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
📍 Icahn School of Medicine at Mount Sinai — New York, New York
Prostate Cancer
View Study & Checklist ➔Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
📍 University of California San Francisco — San Francisco, California
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
View Study & Checklist ➔Study of ORIC-944 in Patients With Metastatic Prostate Cancer
📍 Rocky Mountain Cancer Center — Colorado Springs, Colorado
Metastatic Prostate Cancer
View Study & Checklist ➔A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
📍 Urology Specialists of the Carolinas - University Place — Charlotte, North Carolina
Metastatic Castration Resistant Prostate Cancer
View Study & Checklist ➔Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Prostate Cancer (Adenocarcinoma)
View Study & Checklist ➔Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
📍 AdventHealth Orlando — Orlando, Florida
Prostate CA
View Study & Checklist ➔Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
📍 Mayo Clinic in Arizona — Phoenix, Arizona
Recurrent Castration-Sensitive Prostate Carcinoma
View Study & Checklist ➔